Compare GV & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GV | REVB |
|---|---|---|
| Founded | 2013 | 2020 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2M | 5.1M |
| IPO Year | 2022 | N/A |
| Metric | GV | REVB |
|---|---|---|
| Price | $1.23 | $0.63 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 141.9K | ★ 5.3M |
| Earning Date | 08-14-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,773,905.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.02 | $0.60 |
| 52 Week High | $9.60 | $17.04 |
| Indicator | GV | REVB |
|---|---|---|
| Relative Strength Index (RSI) | 44.95 | 30.42 |
| Support Level | $1.21 | $0.71 |
| Resistance Level | $1.28 | $0.96 |
| Average True Range (ATR) | 0.10 | 0.14 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 16.67 | 4.73 |
Visionary Holdings Inc is a private education providing company located in Canada, with subsidiaries in Canada and market partners in China, that offers high-quality education resources to students around the globe. The company aims to provide access to secondary, college, undergraduate and graduate, and vocational education to students in Canada through technological innovation so that more people can learn, grow, and succeed to their full potential. As a fully integrated provider of educational programs and services in Canada, the company has been serving and will continue to serve both Canadian and international students.
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).